Lexeo Therapeutics joins small class of 2023 biotech IPOs in $100M Nasdaq listing

Lex­eo Ther­a­peu­tics will be­gin trad­ing on the Nas­daq on Fri­day morn­ing via a $100 mil­lion ini­tial pub­lic of­fer­ing.

The car­diac and Alzheimer’s gene ther­a­py biotech priced at $11 per share $LX­EO. In a sign of the drea­ry year for biotech list­ings, Lex­eo priced $2 per share be­low the low end of the range it pro­posed on Mon­day. The Wall Street de­but en­tails sell­ing 9.09 mil­lion shares, which is slight­ly above the 9 mil­lion it had pen­ciled in ear­li­er this week. Lex­eo said Thurs­day night it would al­so give un­der­writ­ers an op­tion to buy an­oth­er 1.36 mil­lion shares with­in 30 days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.